(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Tracking down the Right Equilibrium: Charges versus Personal Costs in Senior Protection. - 2The Main 15 Powerful Business Heads of Today
- 3San Francisco sues 10 companies that make ultraprocessed food
- 4The 2026 'Super Bowl of Astronomy' starts today — here's what's happening
- 520-year-old who threatened German train attack remanded in custody
- NASA's moon mission has begun — here's what's ahead for the Artemis II astronauts
- Iran war upends aviation strategies
- Vote in favor of your Number one natural product
- Apollo vs. Artemis: What to know about NASA's return to the moon
- EU states agree first step for Ukraine reparations fund
- Old video misrepresented as senior Sri Lankan ruling party member criticising president over fuel shortage
- FBI arrests Brian Cole Jr. in Jan. 6 pipe bomb investigation, ending 5-year hunt
- Amplifying Cash The executives: The Upsides and downsides of Various Ledgers
- Judge sets $60K bond for Florida congresswoman accused of stealing $5M in COVID-19 funds
